Streetbeat News

Earnings

NBTX

Nanobiotix (NASDAQ:NBTX) presented new data at ASCO 2024 from their Phase 1 Study 1100, showing promising results for their radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors in patients with advanced solid and metastatic tumors. The study showed a 48% ORR in anti-PD-1 naïve patients and a 28% ORR in anti-PD-1 resistant patients.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:42 pm

NTLA

Intellia Therapeutics announced that a single dose of NTLA-2002 led to a 98% mean reduction in monthly hereditary angioedema (HAE) attack rates, with an average follow-up of over 20 months. The data, presented at the EAACI Congress 2024, showed that 8 out of 10 patients remained attack-free and all patients who discontinued prophylaxis treatment remained free of chronic prophylaxis. The therapy demonstrated a favorable safety and tolerability profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:38 pm

AZN

AstraZeneca announced that its drug Imfinzi significantly reduces the risk of death by 27% compared to placebo in a global Phase III trial for limited-stage small cell lung cancer. The trial results showed a 57% survival rate at three years and will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:16 pm

ALXO

ALX Oncology Holdings Inc. (NASDAQ: ALXO) presented promising Phase 1 ASPEN-07 clinical trial data at the 2024 ASCO Annual Meeting, showing tumor reduction in the majority of evaluable patients with advanced bladder cancer.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:13 pm

PBYI

Puma Biotechnology (NASDAQ:PBYI) presented findings from a Phase II study of alisertib in endocrine-resistant metastatic breast cancer at the ASCO 2024 Annual Meeting. The study showed promising clinical activity and a tolerable safety profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:03 pm

FFIE

FSRN

KARS

LCID

RIVN

TSLA

The EV market had a mixed week ending May 31, with Tesla facing modest losses amid weak economic readings. Key events included Tesla's shareholder meeting and recall, Rivian's Q2 warning, Fisker's layoffs, Faraday Future's stock drop, and Lucid's UAE expansion.

Portfolio Pulse from Shanthi Rexaline

June 01, 2024 | 3:03 pm

AAPL

NVDA

Nvidia Corp. (NASDAQ: NVDA) is closing in on Apple Inc. (NASDAQ: AAPL) to become the world's second most valuable company by market capitalization. Nvidia's market cap has surged to $2.69 trillion, while Apple's stands at $2.94 trillion. Nvidia's stock has increased by over 127% in the first five months of 2024, compared to Apple's 3.6% gain. Analysts are optimistic about Nvidia's continued growth, with some setting a target price of $1,400 for its stock.

Portfolio Pulse from Rounak Jain

June 01, 2024 | 1:45 pm

GME

GOOG

NVDA

TSLA

Benzinga reviewed the performance of popular stocks, highlighting Nvidia's dominance in the AI sector, a Shiba Inu investor's massive profit, GameStop's stock rally after a share offering, and criticisms of Alphabet's search engine quality. The article also covered Tesla's board's response to Glass Lewis's recommendation against Elon Musk's pay package.

Portfolio Pulse from Michael Cohen

June 01, 2024 | 1:32 pm

CGC

Piper Sandler maintains an 'Underweight' rating on Canopy Growth Corporation (NASDAQ:CGC), citing significant valuation adjustments and financial challenges. Despite positive revenue trends, the company faces ongoing efforts to achieve profitability and manage its debt. The rescheduling of cannabis to Schedule III is seen as largely symbolic.

Portfolio Pulse from Nicolás Jose Rodriguez

May 31, 2024 | 8:35 pm

HIVE

Hive Digital Technologies reported mining 212 Bitcoin in April 2024, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 8:29 pm